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background: No study has addressed the failure modes of transcatheter heart valves (THV). We performed a systematic review to investigate the 
causes of THV failure, and to describe the clinical characteristics, diagnosis, management, and outcomes of these patients.
Methods: Between January 2002 and October 2013, all studies reporting patient level data on THV failure were identified. Reports describing only 
an incidence of THV failure were excluded. Prosthetic valve endocarditis (PVE) was defined according to the modified Duke criteria and the other 
outcomes were defined according to VARC.
results: Among 56 separate publications (69 cases) of THV failure, 5 THV failure modes were identified: PVE (n=29), structural valve failure (SVF) 
(n=8), thrombosis (n=12), late embolization (n=13), and compression (n=7). Most (66%) PVE cases had risk factors predisposing to IE: diabetes, 
immunosuppression etc. The microbiological profile of THV PVE was similar to that of surgical PVE. Surgery was performed in 1/3 of cases and 
1/3 ultimately died. THV thrombosis with the Edwards Sapien (n=11) and CoreValve (n=1) occurred at a mean 8±7 months post implantation. 
Most patients (73%) were taking dual antiplatelet agents and 2/3’s were successfully treated with anticoagulation. SVF was attributed to 
leaflet calcification (n=3), cusp rupture (n=1), and THV underexpansion (n=1) or tissue ingrowth (n=1). The failure mode was unclear in 2 cases. 
Management included surgical valve replacement (n=3) or redo THV (n=5). All cases of late THV embolization occurred with the Edwards Sapien THV. 
The time to presentation was 35±41 days and most (n=11) THVs embolized to the left ventricle. Surgical intervention was performed in 92% and 
33% ultimately died. All 7 cases of valve compression occurred with the Edwards Sapien THV in the setting of cardiac arrest. All patients died.
conclusions: Although many THV failure modes are similar to those of surgical bioprostheses, the management of these complications in high-risk 
THV recipients differs substantially from surgical valve patients. THV compression and late embolization represent unique THV failure modes not 
described in the surgical literature.
